Molecular Signatures Associated With Response to ICS Treatment in Patients With COPD Stratified by Eosinophil Levels - Trial NCT06334575
Access comprehensive clinical trial information for NCT06334575 through Pure Global AI's free database. This Phase 4 trial is sponsored by Maria Joyera Rodríguez and is currently Not yet recruiting. The study focuses on Chronic Obstructive Pulmonary Disease. Target enrollment is 135 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Maria Joyera Rodríguez
Fundacion Clinic per a la Recerca Biomédica
Timeline & Enrollment
Phase 4
Jul 01, 2024
Dec 01, 2025
Primary Outcome
Significant molecular changes in COPD stratified by their blood eosinophil counts.
Summary
The 3TR-ICS COPD study is an international, multicentre, randomized, parallel, controlled
 study that will recruit clinically stable former smokers COPD patients (with no exacerbations
 in the previous 8 weeks) on treatment with dual long-acting bronchodilators (LABA+LAMA),
 minimum 8 weeks of usage, not receiving ICS (either naïve or 3 months since last usage).
 The overall objective of this clinical trial is to identify the molecular signatures
 associated with the molecular response to ICS treatment in patients with COPD stratified by
 the levels of circulating eosinophils, and the potential influence of the pulmonary
 microbiome
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06334575
Non-Device Trial